양성 전립선 비대증 치료 시장 : 치료법별, 제품 유형별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Benign Prostatic Hyperplasia Treatment Market is projected to grow by USD 13.96 billion at a CAGR of 6.12% by 2032.

Benign prostatic hyperplasia (BPH) treatment is evolving from broad symptom control toward personalized, risk-stratified management of lower urinary tract symptoms in aging men. BPH prevalence rises sharply with age, and clinical guidance from the American Urological Association (AUA), European Association of Urology (EAU), and NICE supports a stepped pathway that includes watchful waiting, lifestyle modification, alpha blockers, 5-alpha-reductase inhibitors, combination therapy, minimally invasive surgical therapies, and definitive procedures.

Market momentum is supported by global demographic aging, higher diagnosis rates, tele-urology adoption, and patient preference for therapies that preserve sexual function and reduce catheterization, hospitalization, and recovery time. Competitive differentiation increasingly depends on clinical durability, safety, reimbursement access, physician training, and real-world evidence demonstrating outcomes across prostate size, anatomy, comorbidity, and medication history.

Transformative Shifts in the BPH Treatment Landscape

The BPH treatment landscape is shifting as minimally invasive surgical therapies, including prostatic urethral lift, water vapor thermal therapy, temporary implanted prostatic devices, aquablation, and embolization approaches, expand options between long-term medication and traditional surgery. These therapies address demand for faster recovery and lower sexual side-effect burden, while transurethral resection of the prostate, laser enucleation, and other definitive interventions remain important for larger glands, urinary retention, and severe obstruction.

Pharmaceutical strategies are also changing. Alpha blockers remain widely used for rapid symptom relief, while 5-alpha-reductase inhibitors are prioritized for enlarged prostates and disease progression risk. Combination therapy, medication adherence support, and shared decision-making are increasingly central as clinicians balance symptom improvement, adverse effects, cost, and long-term retreatment risk.

Cumulative Impact of Artificial Intelligence on BPH Care

Artificial intelligence is beginning to influence BPH care through imaging interpretation, symptom scoring, workflow automation, clinical decision support, and predictive analytics. AI-enabled tools can help urologists evaluate prostate volume, bladder outlet obstruction risk, medication response probability, and post-procedure complications when integrated with validated clinical data and physician oversight.

The cumulative impact is most visible in care pathway efficiency. Digital intake, remote monitoring, natural-language processing of clinical notes, and AI-assisted triage can reduce delays from symptom onset to specialist evaluation. However, adoption depends on transparent algorithms, bias monitoring, cybersecurity, regulatory compliance, and validation across diverse populations because BPH outcomes vary by age, anatomy, comorbidities, and access to urologic care.

Key Regional Insights: BPH Treatment Demand by Geography

Asia-Pacific is a high-growth region for BPH treatment due to rapid aging in China, Japan, South Korea, and Australia, combined with expanding specialist capacity in India and ASEAN markets. Japan is among the world's oldest societies, and China and South Korea are experiencing sustained growth in older male populations, strengthening demand for diagnostic evaluation, chronic medication, and minimally invasive treatment. North America remains a major innovation and reimbursement hub, supported by high urology procedure volumes, Medicare-aged demand in the United States, strong adoption of minimally invasive technologies, and established guideline-based care.

Europe benefits from structured health technology assessment, broad clinical guideline alignment, and mature urology service networks, particularly across the European Union and the United Kingdom. Latin America shows rising demand as Brazil and Mexico expand private healthcare access and urban specialty care capacity, although affordability and uneven access continue to affect treatment uptake. The Middle East, led by GCC investment in specialty hospitals and tertiary care, is increasing access to advanced urologic procedures. Africa remains more uneven, with BPH treatment access linked to urban hospital investment, workforce development, diagnostic availability, and improved access to essential urology services.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are characterized by rising diagnosis, medical tourism corridors, and expanding private hospital networks, creating opportunities for cost-effective medications and scalable minimally invasive BPH procedures. GCC countries are investing in tertiary care, robotic surgery infrastructure, and international clinical partnerships, supporting adoption of advanced urology platforms among high-income patient populations and expatriate communities.

The European Union emphasizes evidence, safety, procurement value, and reimbursement discipline, favoring BPH treatment products supported by comparative outcomes and durable data. BRICS countries represent substantial long-term clinical need due to large aging male populations, but access, pricing, hospital infrastructure, and reimbursement vary widely across member economies. G7 markets generally lead in technology adoption, clinical trial activity, and guideline implementation, while NATO-aligned systems outside the G7 often follow European and North American standards for training, quality, device regulation, and health system readiness.

Key Country Insights: Priority BPH Treatment Markets

The United States is a leading environment for BPH treatment innovation, supported by specialty urology networks, Medicare-aged demand, and availability of minimally invasive and surgical options. Canada shows steady demand through publicly funded pathways and private adjunct services, while Mexico and Brazil combine expanding middle-class healthcare access with large populations that remain underdiagnosed or undertreated. In Europe, the United Kingdom, Germany, France, Italy, and Spain emphasize guideline-based care, reimbursement evidence, clinical efficiency, and procedure quality; Russia maintains demand from an aging male population but faces access, affordability, and supply-chain variability.

China and India represent major long-term opportunities because of aging demographics, improving diagnostic penetration, and expanding hospital capacity, although affordability and hospital tier differences shape uptake. Japan and South Korea support advanced procedural adoption due to aging populations, sophisticated health systems, and high expectations for functional outcomes. Australia shows strong alignment with evidence-based urology practice and private-sector access to newer procedures, reinforcing demand for therapies that reduce recovery time and preserve quality of life.

Actionable Recommendations for BPH Treatment Industry Leaders

Industry leaders should prioritize differentiated clinical evidence that compares symptom improvement, urinary flow, retreatment rates, sexual function preservation, adverse events, catheter dependence, and recovery time across therapies. Evidence packages should be designed for urologists, payers, procurement committees, and patients, with real-world registries strengthening claims beyond pivotal trials.

Commercial execution should combine physician education, patient decision aids, reimbursement strategy, and service-line partnerships with high-volume urology centers. Organizations should localize pricing, training, and distribution models for emerging markets while maintaining regulatory quality. Digital symptom tracking, AI-assisted care navigation, and post-procedure monitoring can improve adherence, patient satisfaction, and longitudinal outcome measurement.

Research Methodology

This executive summary is grounded in secondary research from recognized clinical and public health sources, including urology guidelines, peer-reviewed literature, regulatory updates, hospital practice trends, demographic data, and reimbursement frameworks. Evidence was assessed for clinical relevance to BPH treatment pathways, including pharmacologic therapy, minimally invasive interventions, and surgical management.

The methodology emphasizes triangulation across guideline recommendations, epidemiology, technology adoption signals, and regional healthcare access indicators. Insights were structured to support strategic planning, market prioritization, executive communication, and decision-making for stakeholders across medical devices, pharmaceuticals, digital health, provider organizations, and healthcare investors.

Conclusion

BPH treatment is moving toward more personalized, less invasive, and data-enabled care. Aging populations, rising patient expectations, and expanding procedure portfolios are increasing demand for solutions that improve urinary symptoms while limiting recovery time and preserving quality of life.

The strongest opportunities will favor organizations that combine durable clinical outcomes, physician training, patient-centered education, payer-ready evidence, and responsible digital innovation. As AI, minimally invasive therapies, and regional healthcare investment converge, the BPH treatment landscape is positioned for sustained transformation across developed and emerging health systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

• 7.1. Medications
  • 7.1.1. 5-Alpha-Reductase Inhibitors
  • 7.1.2. Alpha Blockers
• 7.2. Minimally Invasive Therapies
  • 7.2.1. Prostate Artery Embolization
  • 7.2.2. Water Vapour Therapy
• 7.3. Surgical Treatments
  • 7.3.1. Laser Surgery
  • 7.3.2. Prostatic Urethral Lift
  • 7.3.3. Transurethral Incision Of The Prostate
  • 7.3.4. Transurethral Resection Of The Prostate

8. Benign Prostatic Hyperplasia Treatment Market, by Product Type

• 8.1. Catheters
• 8.2. Electrodes
• 8.3. Implants
• 8.4. Prostatic Stents
• 8.5. Resectoscopes
• 8.6. Urology Laser

9. Benign Prostatic Hyperplasia Treatment Market, by End User

• 9.1. Ambulatory Surgical Centers
• 9.2. Clinics
• 9.3. Homecare
• 9.4. Hospitals

10. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel

• 10.1. Offline
• 10.2. Online

11. Benign Prostatic Hyperplasia Treatment Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Benign Prostatic Hyperplasia Treatment Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Benign Prostatic Hyperplasia Treatment Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AbbVie Inc.
• 15.2. Alembic Pharmaceuticals Limited
• 15.3. Asahi Kasei Corporation
• 15.4. Astellas Pharma Inc.
• 15.5. Bayer AG
• 15.6. Boehringer Ingelheim GmbH
• 15.7. Boston Scientific Corporation
• 15.8. Cipla Ltd.
• 15.9. Coloplast Group
• 15.10. Dr. Reddy's Laboratories
• 15.11. Eli Lilly and Company
• 15.12. Endo International PLC
• 15.13. GlaxoSmithKline plc
• 15.14. Hikma Pharmaceuticals PLC
• 15.15. IPG Photonics Corporation
• 15.16. Lumenis Ltd.
• 15.17. Olympus Corporation
• 15.18. Organon group of companies
• 15.19. PROCEPT BioRobotics Corporation
• 15.20. ProstaLund AB
• 15.21. Quanta System
• 15.22. Richard Wolf GmbH
• 15.23. Teleflex Incorporated
• 15.24. Urologix, LLC.